Alligator CEO Provides Snapshot Of Tumor-Directed IO Pipeline

09 Mar 2018

• By Mike Ward

Following a deal, worth potentially $700m plus, signed in 2015 with Johnson & Johnson’s Janssen Biotech, Swedish biotech Alligator Biosciences AB is well placed to drive its clinical pipeline. During the Biotech Showcase, CEO Per Norlén outlined to Scrip the current status of the pipeline and its plans moving forward, which include having five clinical programs in place by the end of 2019.

With programs designed for tumor-directed immunotherapy, focusing on immunostimulatory receptors and aimed at providing long-lasting protection against cancer, Swedish biotech Alligator Bioscience AB, according to CEO Per Norlén, has enough money to enable it to progress five clinical programs to Phase II proof of concept. That is the inflexion point at which it ideally will seek pharma partners to further develop the programs.

Open Media